Susan Margaret Sundström
Corporate Officer/Principal presso The University of Southampton
Profilo
Susan Margaret Sundström is currently a Principal at The University of Southampton.
Previously, she was a Non-Executive Director at Synairgen Plc from 2003 to 2009, and a Non-Executive Director at Karus Therapeutics Ltd.
She also held a position as a Principal at AstraZeneca PLC.
Posizioni attive di Susan Margaret Sundström
| Società | Posizione | Inizio |
|---|---|---|
| The University of Southampton | Corporate Officer/Principal | - |
Precedenti posizioni note di Susan Margaret Sundström
| Società | Posizione | Fine |
|---|---|---|
| SYNAIRGEN PLC | Direttore/Membro del Consiglio | 03/09/2009 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SYNAIRGEN PLC | Health Technology |
| Aziende private | 1 |
|---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Susan Margaret Sundström
